Theralase Presents Dosimetry Planning at International World Congress
Accesswire AccesswireJune 13, 2017
TORONTO, ON / ACCESSWIRE / June 13, 2017 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds ("PDCs") to destroy cancer, announced todaythat its latest research on dosimetry planning and Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study data ("Study") was recently presented on June 9th, at the 16th International Photodynamic Association ("IPA") World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal.
The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy ("PDT") and Photo Diagnosis ("PD"). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers ("PSs"), and disseminates this knowledge to IPA members, the medical community and the general public. The IPA World Congress is held every two years and is quickly becoming known as the premier forum to communicate outstanding advances in the clinical and research aspects of PDT and PD.
The clinical data for the initial three patients treated in the Study with the recommended starting dose of TLD-1433 PDC (0.35 mg/cm2), which laid the groundwork for an advanced, personalized and patient specific PDT platform technology was presented at the 16th IPA World Congress.
Theralase is using the Study to evaluate its lead PDC, TLD-1433, for the: primary endpoint of safety and tolerability, secondary endpoint of Pharmaco Kinetics ("PK") (movement and exit of drug within tissue) and exploratory endpoint of efficacy.
